Thrivent Financial For Lutherans Enanta Pharmaceuticals Inc Transaction History

Thrivent Financial For Lutherans

$52.6 Billion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$8.18 - $10.78 $4,310 - $5,681	-527 Reduced 4.8%	10,460 $98,000
Q3 2023 Nov 14, 2023	SELL	$11.09 - $22.13 $438,831 - $875,684	-39,570 Reduced 78.27%	10,987 $123,000
Q2 2023 Aug 14, 2023	BUY	$20.68 - $39.85 $93,411 - $180,002	4,517 Added 9.81%	50,557 $1.08 Million
Q1 2023 May 17, 2023	BUY	$38.82 - $54.59 $1.01 Million - $1.42 Million	26,057 Added 130.4%	46,040 $1.86 Million
Q4 2022 Feb 08, 2023	SELL	$40.77 - $53.73 $6,319 - $8,328	-155 Reduced 0.77%	19,983 $930,000
Q3 2022 Nov 14, 2022	BUY	$48.29 - $71.27 $97,883 - $144,464	2,027 Added 11.19%	20,138 $1.05 Million
Q2 2022 Aug 16, 2022	BUY	$38.13 - $76.93 $124,036 - $250,253	3,253 Added 21.89%	18,111 $856,000
Q1 2022 May 13, 2022	BUY	$56.06 - $74.11 $12,108 - $16,007	216 Added 1.48%	14,858 $1.06 Million
Q4 2021 Feb 16, 2022	BUY	$60.19 - $97.37 $5,958 - $9,639	99 Added 0.68%	14,642 $1.1 Million
Q3 2021 Nov 15, 2021	SELL	$41.02 - $58.65 $6,153 - $8,797	-150 Reduced 1.02%	14,543 $826,000
Q2 2021 Aug 19, 2021	SELL	$43.76 - $53.11 $2,406 - $2,921	-55 Reduced 0.37%	14,693 $647,000
Q1 2021 May 17, 2021	SELL	$41.69 - $54.95 $1,834 - $2,417	-44 Reduced 0.3%	14,748 $727,000
Q4 2020 Feb 16, 2021	SELL	$41.16 - $47.47 $864 - $996	-21 Reduced 0.14%	14,792 $623,000
Q3 2020 Nov 10, 2020	BUY	$43.36 - $53.53 $54,243 - $66,966	1,251 Added 9.22%	14,813 $678,000
Q2 2020 Aug 12, 2020	BUY	$46.37 - $57.58 $7,929 - $9,846	171 Added 1.28%	13,562 $681,000
Q1 2020 May 15, 2020	BUY	$40.22 - $62.0 $26,866 - $41,416	668 Added 5.25%	13,391 $689,000
Q4 2019 Feb 13, 2020	SELL	$57.95 - $66.61 $973,212 - $1.12 Million	-16,794 Reduced 56.9%	12,723 $786,000
Q3 2019 Nov 14, 2019	BUY	$60.08 - $88.17 $1.03 Million - $1.51 Million	17,074 Added 137.22%	29,517 $1.77 Million
Q2 2019 Aug 13, 2019	BUY	$81.3 - $97.35 $35,853 - $42,931	441 Added 3.67%	12,443 $1.05 Million
Q1 2019 May 14, 2019	BUY	$69.08 - $105.66 $62,862 - $96,150	910 Added 8.2%	12,002 $1.15 Million
Q4 2018 Feb 15, 2019	BUY	$65.41 - $84.65 $15,894 - $20,569	243 Added 2.24%	11,092 $786,000
Q3 2018 Nov 15, 2018	BUY	$85.46 - $126.37 $79,990 - $118,282	936 Added 9.44%	10,849 $927,000
Q2 2018 Aug 14, 2018	BUY	$81.85 - $120.51 $50,255 - $73,993	614 Added 6.6%	9,913 $1.15 Million
Q1 2018 May 08, 2018	BUY	$57.91 - $92.15 $22,758 - $36,214	393 Added 4.41%	9,299 $752,000
Q4 2017 Feb 14, 2018	BUY	$45.65 - $59.37 $8,034 - $10,449	176 Added 2.02%	8,906 $523,000
Q3 2017 Nov 14, 2017	BUY	$37.91 - $46.8 $330,954 - $408,564	8,730	8,730 $409,000

Others Institutions Holding ENTA

# of Institutions

110

Shares Held

21.1M

Call Options Held

4.8K

Put Options Held

4.6K

Farallon Capital Management LLC San Francisco, CA

2.11M
Shares

$19.7 Million
0.11% of portfolio
Vanguard Group Inc Valley Forge, PA

1.98M
Shares

$18.5 Million
0.0% of portfolio
Black Rock Inc. New York, NY

1.85M
Shares

$17.3 Million
0.0% of portfolio
Krensavage Asset Management, LLC New York, NY

1.5M
Shares

$14 Million
8.7% of portfolio
Morgan Stanley New York, NY

1.1M
Shares

$10.3 Million
0.0% of portfolio

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $194M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.

Account